Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.

Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a ...

With a new treatment for prostate cancer in play, men with more aggressive forms of prostate cancer may have a more positive ...

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

When prostate cancer metastasizes, spreads outside of the prostate itself, it typically affects the structures in its immediate vicinity. Structures near the prostate likely to be involved include ...

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

Restaurant critic and journalist Giles Coren has become the latest well-known figure to announce his diagnosis of prostate cancer. It comes in the same week the form of cancer was revealed as the ...

Restaurant critic and journalist Giles Coren has announced his diagnosis with prostate cancer. Writing in his column for The Times, the 55-year-old said urology nurses had taken a biopsy before ...